Reunion Neuroscience Inc. Common Shares (REUN)

REUN was delisted on the 31st of July, 2023.

• Market cap: $13.1M
• Sector: Healthcare
• Industry: Medical Care Facilities

About: Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Employees: 16